Epidemic Update and Risk Assessment of 2019 Novel Coronavirus
Chinese Center for Disease Control and Prevention
2019-nCoV Emergency Response Level I (highest)
Epidemic Analysis and Risk Assessment Group
28 January 2020
Abstract
According to the results of field investigation, laboratory testing, and the known knowledge of the
coronavirus, it is speculated that the 2019 Novel Coronavirus (2019-nCoV) originated from wild
animals, even though the host animal(s) is still under investigation. Though unconfirmed whether
virus spillage spill over from animal to human occurred at Wuhan South China Seafood Wholesale
Market, it was the main place of infection for the early cases of this epidemic. As of 27 January 2020,
National Health Commission (NHC) of China reported 4535 confirmed cases from 30 provinces
(including municipalities and autonomous regions) and Hong Kong Special Administrative Region,
Macao Special Administrative Region, and Taiwan area, there were 976 severe cases and 106 deaths.
As of 26 January, confirmed cases have also been reported in 10 other countries, including: 7 cases in
Thailand, 3 cases in Japan, 3 cases in South Korea, 3 cases in USA, 2 cases in Viet Nam, 4 cases in
Singapore, 3 cases in Malaysia, 1 case in Nepal, 3 cases in France and 4 cases in Australia.
Chinese authorities at all levels have implemented strong control and prevention measures. The
measures include: frequent public media communications to enhance the awareness of disease
prevention among people; stopping mass gatherings, encouraging people to reduce personal
gatherings and wear face masks to reduce the chance of infection. Cellphone GPS back tracking
technology, travelling and visiting history investigations and other measures have been taken to
improve the early detection of cases and reduce spreading. Moreover, hospital infection prevention
and control are highly emphasized to prevent nosocomial infection. In Wuhan, public transportation
has been temporarily closed, including bus, subway, ferry and long-distance transportation services.
Citizens are advised to stay in Wuhan unless they have a special reason to travel. Airports and train
stations were also shut down. Twelve prefectures in Hubei province also triggered traffic control
actions according to their local situations.
The 2019-nCoV has transmitted from human to human for more than one month, and it is still in the
early stage of community transmission. As the efficient and strong control measures have been taken
by Chinese governments and people, the containment of this epidemic of 2019 nCoV will meet
expected effects, and a larger epidemic or even pandemic will be prevented.
1. Background
On 29 December 2019, the health authorities in Hubei Province and Wuhan City received a report of
a cluster of pneumonia cases of unknown etiology from a local hospital, and all four patients were
employees of the Wuhan Huanan(South China) Seafood Wholesale Market (HN market for short).
Local health departments started investigation and case-searching on 31 December 2019. That same
day, National Health Commission (NHC) and China CDC stepped into the investigation and the Wuhan
government released information on the disease outbreaks.
On January 1, 2020, based on preliminary findings, the HN market was temporarily closed. To identify
causes of the unknown pneumonia, Wuhan City launched surveillance, case finding, environmental
sampling and animal surveys at the HN market. By 8 January 2020, Chinese authorities had identified
a new virus linked with the outbreak of disease, “2019-nCoV”. By 10 January 2020, China CDC had
shared the virus's full gene sequence with the WHO and other countries and began developing and
testing PCR assays to detect and diagnose suspected cases in Wuhan.
On 15 January, the NHC issued guidelines for the diagnosis, treatment, prevention and control of
pneumonia associated with 2019-nCoV. These guidelines regulated case monitoring, reporting,
1
diagnosis and treatment, management, close contact management and laboratory testing. On 20
January, the State Council agreed to include the 2019-nCoV pneumonia into the Management of the
Infectious Diseases Law and the Health and Quarantine Law. On 21 January, the China CDC published
the probe and primer sequence of PCR reagents. Wuhan and other cities in Hubei have suspended
public transportation to varying degrees since 23 January. On 25 January, the Central Committee of
the Communist Party of China (CPC) set up a leading group to deal with this epidemic, under the
leadership of the Standing Committee of the Political Bureau of the CPC Central Committee, to carry
out the prevention and control of the pneumonia outbreak of the 2019-nCoV infection, and upgrade
the level of emergency response comprehensively.
2. Epidemic status and critical knowledge of the disease
2.1 Epidemic update
From 00:00 to 24:00 of 27th January, 30 provinces (autonomous regions and municipalities) in the
mainland reported 1771 new confirmed cases, 515 new severe cases, 26 new deaths (all in Hubei), 9
new cured and discharged cases, and 2077 new suspected cases.
As of 24:00 on 27th January, NHC received 4515 cumulative confirmed cases, 976 severe cases, 106
deaths, 60 cured and discharged cases and 6973 suspected cases from 30 provinces (autonomous
regions and municipalities) in the mainland.
Currently 47833 cumulative close contacts have been tracked while 44132 people are under medical
observation.
Besides, Hong Kong Special Administrative Region(China) reported 8 cases, Macao Special
Administrative Region(China) reported 7 cases, Taiwan area(China) reported 5 cases.
As of 26 January, confirmed cases also reported by 10 other countries: 7 cases in Thailand, 3 cases in
Japan, 3 cases in South Korea, 3 cases in United States, 2 cases in Vietnam, 4 cases in Singapore, 3
cases in Malaysia, 1 case in Nepal, 3 cases in France and 4 cases in Australia.
2
Figure 1. Distribution of 2019-nCoV confirmed cases in China (as of 24:00, 27 January 2020)
Figure 2. Epi-curve of 2019-nCoV in Mainland China (as of 24:00, 27 January 2020)
2019-nCoV in Wuhan continues to spread and the number of cases is still on the rise. The virus has
spread to 11 prefectures of Hubei Province outside Wuhan, including Huanggang, Xiaogan, Jingmen,
Enshi,Xiantao, and others. Outside Hubei, 29 provinces in Mainland China have reported cases. Up to
now, majority of cases are related to Wuhan and some of the local cases are infected by the cases
from Wuhan .
Because of apparent community transmission in Wuhan1 and some areas in Hubei province, mild
early symptoms of the disease, and existence of mild cases, it is difficult to diagnose the disease and
quarantine all patients in time, potentially causing accumulation of infection sources in the
community and increasing the difficulty in controlling the disease. For this reason, the number of
cases in Wuhan and a few other prefectures in Hubei may continue to increase.
In Wuhan, Huanggang, Xiaogan in Hubei province, prevention and control efforts have been
dramatically strengthened through a series of measures , such as suspension of public transport,
cancellation of mass gatherings, strengthening of community mobilization, active screening of fever
patients and strengthened infection prevention and control. Implementation of these measures are
expected to have positive impacts on the control of the disease. The majority of cases in provinces
outside Hubei are imported from Wuhan. There is no apparent community transmission in those
provinces. Currently, all provinces with confirmed cases in mainland China have launched the highest
level emergency response, taking powerful actions, adopting multiple measures and technologies,
using rigorous screening and investigation procedures for early detection and isolation of imported
cases, and quarantine of their close contacts, in order to stop community transmission.
2.2 Developing case definitions
1
Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia[J]. New
England Journal of Medicine,2020. DOI: 10.1056/NEJMoa2001316
3
1) Suspected Case
According to the first edition of Guidelines for Diagnosis and Treatment of Pneumonia associated with
2019-nCoV, “observation case” is defined as a person who meets the following two conditions. First,
travel to Wuhan within 14 days before the onset of symptoms, or direct/indirect exposure to wet
markets in Wuhan within 14 days before the onset of symptoms. Second, the person develops fever,
imaging features of pneumonia, normal or decreased total white cell number in early stage or
decreased leukomonocyte number, not improving or progressively aggravating after 3 days of
standard antimicrobial therapy (the standard as per “Chinese adults community-acquired pneumonia
diagnosis and treatment norms (2016)” and “Chinese children community-acquired pneumonia
diagnosis and treatment norms (2019)”).
On 18 January, the second edition changed “observation case” into “suspected case”. There were
suspected cases from outside Hubei who had no exposure to Wuhan wet markets, thus the suspect
case definitions changed to the following two conditions. First, the person has a history of traveling
to or residing in Wuhan within 14 days before the onset of symptoms, or had a contact with patients
from Wuhan with fever or respiratory symptoms within 14 days, or belongs to a cluster of similar
illness. Second, the person develops fever, imaging features of pneumonia with specific description,
normal or decreased total white cell numbers in early stage or decreased leukomonocyte numbers.
The condition of “after three days of standard antimicrobial therapy” is removed in order to diagnose
a case as early as possible. The procedure of diagnosis of the first suspected case outside Hubei
Province: a positive RNA test results from the provincial CDC, a positive RNA retest result from China
CDC or a third-party institution, and confirmation by the diagnosis team under the Epidemic
Response Leadership Group of NHC.
In the third edition, released on January 22nd, no change was made in the definition of a suspected
case, but the procedure for reporting a suspected case changed. Medical practitioners in hospitals
should now instantly quarantine the patient, provide treatment and report to the relevant infection
control department of the hospital and local CDC. The hospital will organize expert group
consultations within two hours. If the patient’s diagnosis cannot be attributed to a common
respiratory pathogen, his/her samples should be collected and sent for 2019 nCoV testing.
On 27 January, the fourth edition was released, again with the definitions for suspected case based
on the definitions in previous editions. A third condition was added to the epidemiological
assessment, requiring that the person be in a cluster of or have an epidemiological link to confirmed
cases or patients without pneumonia who tested positive for 2019-nCoV. A person who meets any
one of the three epidemiological history conditions and any two conditions of clinical manifestations
is a suspected case. A person who has no epidemiological history, but has all the 3 conditions of
clinical manifestations is also defined as a suspected case.
2) Confirmed case
In the first edition, if the observation case’s respiratory tract specimens such as sputum and throat
swabs are positive for the whole genome of the virus sequence, which is highly homologous with
2019-nCov, it is defined as a confirmed case.
The second edition defines a confirmed case as follows: if the suspected case’s specimens of sputum,
throat swabs, lower respiratory tract secretions, and other specimens test positive for the 2019-nCoV
nucleic acid by real-time fluorescent RT-PCR; or the viral gene sequence is highly homologous to
2019-nCoV. For suspected cases, the virus genome sequencing is performed by China CDC or a
designated third-party laboratory, and the sequence received should be highly homologous with
4
2019n-CoV. Final confirmation is based on the clinical manifestations, epidemiological history and
laboratory test results by the diagnostic team under the Epidemic Response Leadership Group of
NHC.
For the third edition the confirmed case is the same as the second edition. The diagnostic procedure,
however, was changed: for the first case in provinces other than Hubei, provincial CDC should send
samples to China CDC or a designated third party laboratory for validation, and no need for
confirmation by the diagnostic team under the Epidemic Response Leadership Group of NHC .
The definition of the confirmed case in the fourth edition is based on the third edition, to which a
requirement was added that blood samples be tested positive by real-time fluorescent RT-PCR. The
confirmation procedure was changed to require that the first case or clustered cases in each county
be confirmed by prefecture CDC. The samples from cluster cases should be submitted to the
provincial CDC and China CDC for further testing. If large-scale sustained community transmission
occurs, the confirmation can be done by the laboratories in hospitals which are authorized after
assessment by the prefectural CDC.
2.3 Key knowledge of 2019-nCoV to date
Fever, fatigue, and dry cough are the main manifestations, with nasal congestion, runny nose and
diarrhea seen in few patients. Severe cases showed dyspnea one week later, and severe cases rapidly
progressed to acute respiratory distress syndrome, septic shock, hard-to-correct metabolic acidosis,
and bleeding and coagulation dysfunction. It is worth noting that severe and critically ill patients can
show moderate to low fever, and even no obvious fever. Some patients showed only low fever and
slight fatigue, without pneumonia, and usually recovered after 1 week.
The current male-to-female ratio of all detected cases is 1.2:1. The median age was 48 years, ranging
from 9 months to 96 years, with less than 0.6% of cases under the age of 15 years. The incubation
period is approximately 3-7 days. Older patients and patients with underlying diseases are prone to
severe illness and death. 2019-nCoV nucleic acid has been found in influenza-like illness cases in
routine surveillance specimens, and there is some evidence of inapparent infection. Therefore, it is
speculated that the severity and fatality rate may be lower than the proportion of reported severe
cases and deaths to the reported confirmed cases. The clinical infection spectrums are still under
investigation.
The results of the field investigation, laboratory testing, and knowledge of other known
coronaviruses indicates that the 2019 Novel Coronavirus (2019-nCoV) originated in wild animals,
even though the host animal(s) are still under investigation. Although it remains to be further
confirmed whether the spill over from animals to humans and the completion of adaptive mutation
of the virus occurred in HN Market, it was the main source of infection for the early cases of this
epidemic. Current evidence suggests that the main routes of transmission of the virus are through
respiratory droplets and close contact. The virus is highly contagious, and its basic reproduction
number (R0) is believed to be between 2 and 3. To date, there is no reliable evidence from the field
investigations that the disease is contagious during the incubation period.
3.Public health measures
3.1 Prevention and control during the spread period centered with HN market
When the preliminary investigation indicated that the epidemic was spreading around the HN market,
5
the market was immediately closed. At the same time, all cases were isolated and treated and close
contacts tracked and followed up. Environmental samples from the HN market were collected and
tested, and cases finding, contact tracing, and investigating the sources of infection were taken.
3.2 Prevention and control during community transmission in Wuhan
Since January 15, suspected cases with travel history to Wuhan were monitored in other regions of
China to detect imported cases as early as possible and prevent local transmission. In Wuhan, case
surveillance and close contact tracing and management were further strengthened.
Recognizing that 95% of cases detected outside Wuhan were infected during their stay in Wuhan,
Wuhan’s city buses, subways, ferries, and long-distance passenger transportation were suspended
from 23 January on. Citizens of Wuhan were advised not to leave Wuhan without a special reasons.
Airports and railway stations’ departure channels from Wuhan were temporarily closed. All these
measures were taken to reduce the bidirectional flow of people.
3.3 The period when there are signs of early community transmission in other areas outside Wuhan
After January 23, in addition to Wuhan, the other 12 prefecture-level cities in Hubei Province have
suspended public transport, stopped crowd gathering activities, strengthened community prevention
and control, actively detected and diagnosed patients with fever, and strengthened patient admission.
The work of prevention and control has been significantly strengthened.
Since January 20, the Chinese government has launched joint prevention and control mechanisms
among 33 central governmental departments, and a series of measures have been taken, including:
very frequent media communication and public communication to raise awareness of disease
prevention, stopping mass gathering, encouraging people to reduce personal gatherings and wear
face masks to reduce the chance of infection. Cellphone GPS back tracking technology, travelling and
visiting history investigations and other measurements have been taken to improve the early
detection of cases and reduce spreading. Moreover, hospital infection prevention and control is
highly emphasized to prevent nosocomial infection.
From January 25, China's top leaders have directly led the prevention and control of the epidemic,
and stronger prevention and control measures will be taken nationwide to control the epidemic. As
of January 25, all 30 provinces in China that have reported cases of pneumonia associated with new
coronavirus have launched a level I response to public health emergencies (highest level).
4. Risk assessment
The current etiological and epidemiological evidence suggests that 2019-nCoV may have first
occurred in Wuhan, Hubei Province from December 2019. At present, the epidemic is still in the early
stage of community transmission, and the vast majority of cases found in other provinces and other
countries are related to Wuhan. More and more community sporadic cases without a clear
epidemiological history have been found in Wuhan, and infection has occurred in health care workers,
which indicating human-to-human transmissibility. At the same time, secondary infections caused by
imported cases also occurred in domestic areas outside Wuhan, and the epidemic spread to more
foreign countries.
Current evidence suggests that the 2019 nCoV has been spreading in humans for more than a month.
The main epidemic areas are concentrated in and around Wuhan, and the epidemic is still in its early
stage. Authorities at all levels in China have taken strong response measures: mobilized social forces
to promote case detection and management to avoid further transmission; enhanced infection
6
control to avoid outbreaks of nosocomial infection; and encouraged the public to reduce gatherings,
travel, wear masks and wash hands frequently to reduce exposure and infection opportunities. In
Wuhan, vigorous measures have been taken such as suspension of urban bus, subway, ferry and
long-distance passenger transport, and temporary closure of airports and railway stations. Other
prefectures in Hubei Province around Wuhan have also adopted varying degrees of traffic control to
restrict the movement and gathering of people. As efficient and strong control measures have been
taken by Chinese governments and people, the containment of this epidemic of 2019 nCoV will meet
expected effects, and a larger epidemic or even pandemic will be prevented.
With the efficient and strong control measures taken by Chinese government and people, the
containment of this epidemic of 2019 nCoV will meet expected effects, and a larger epidemic or even
pandemic will be prevented.
5. Future measures
China will continue to make great efforts to the community mobilization, which mainly depends on
sub-district (township) and community (village) cadres, primary health care centers and family
doctors (village doctors). At the same time, residents and volunteers are encouraged to participate in
the full- or part-time working teams engaging in door-to-door health promotion, case detection and
management. Early referral of patients to hospital for medical treatment and management should be
ensured to avoid further transmission. Medical doctors and nurses will be mobilized nationwide and
deployed to support epidemic center areas, in order to restore normal medical care as soon as
possible. The cases will be isolated and treated, and the nosocomial infection control will be
effectively implemented. In addition, home isolation of mild cases under the guidance of health
professionals is encouraged, to reduce the burden on health care system and prevent nosocomial
transmission. China will continue to advocate preventive measures such as reducing gathering,
reducing unnecessary travel, wearing masks and washing hands frequently to reduce the chances of
exposure and infection.
Facing a new infectious disease, China will update the prevention and control strategy based on the
major changes of evidences from surveillance, investigation and research.
China will continue to strengthen communication and cooperation with the World Health
Organization and relevant countries and areas.
Acknowledgement
We thank Dr Chin-Kei Lee, China-WHO Country Office, Dr Anna A. Drexler and Karen Nahapetyan,
WHO Regional Office for the Western Pacific, for their valuable opinions about English wording in this
report.
7
Epidemiological investigation of pneumonia cases infected with 2019-nCoV ( Th ird E dition , Jan 28, 2020 ) This protocol is specifically developed to collect epidemiological information including the incidence, exposure history, and contact history of pneumonia cases infected by the 2019 Novel Coronavirus ( 2019-nCoV ), to trace close contacts to determine if anyone else has become ill, and to prevent possible spread and transmission of pneumonia cases caused by the 2019-nCoV. I. Objectives 1.1 To investigate the incidence, medical care seeking, clinical symptom s, risk factors and history of exposure; 1.2 To identify and manage close contacts of cases with 2019-nCoV . 2. Subjects for investigation Suspected cases, confirmed cases, mild cases, asymptomatic pneumonia cases infected with 2019-nCoV , and clustered cases of the pneumonia caused by 2019-nCoV. 3. Investigation contents and methods 3.1 Case investigation. After receiving the report of the case of 2019-nCoV, the Center for Disease Control and Prevention (CDC) at the county/district level should complete the epidemiological case investigation within 24 hours, which can be carried out by reviewing document, interviewing cases, informants and physicians. If the health condition of the case permits, the case should be investigated first, and then his/her physicians, family members, and informants could be interviewed. The contents of investigation includes basic demographic information, onset and treatment, exposure history and risk factors, laboratory tests, close contacts, etc. S ee the attached table for details. 1. Basic information : name, gender, age, address, contact information, etc. 2. Onset and d iagnosis & t reatment : clinical manifestations, process from onset of symptoms to care seeking . 3. Risk factors and history of exposure : Investigation of the history of exposure within 14 days before the onset of the case, mainly to investigate the history of travel or residence in Wuhan or other areas where local transmission of virus persists before the onset of illness, the history of contact with patients with fever or respiratory symptoms, visits to hospitals, farmer's market and other related exposure history. 4 .Laboratory testing : specimen type, sampling time, test results, etc. 5. Identification of close contacts : Close contacts are identified via tracing and screening their activities and contacts with population after the the onset of illness of suspected cases, confirmed cases, or mild cases who already present the symptoms , or those with asymptomatic infection but being tested as positive with novel coronavirus. Definition and determination of close contacts follows the instructions in the Management of c lose contacts of p neumonia cases with n ew c oronavirus infection (Third Edition). 3.2 Cluster i nvestigation . The county (district) level disease control agency shall, based on the internet-based report and case investigation report , and the definition of the Surveillance Plan on the novel c oronavirus Infected Pneumonia (Third Edition) to determine whether an aggregated epidemic occur , and conduct an investigation immediately . In addition to information on the source of infection and close contacts of all cases, the investigation shall focus on investigating the epidemiological links among cases, analyzing the chain of transmission, and f ill in the basic information, initial, progress and final report of the incident in accordance with the requirements stipulated in the National Working Standards for the Management of Information Reports on Public Health Emergencies (Trial) . Organization and implementation According to the principle of "Localized Management", the health administrative department at the county/city/district level, where the place of the case’s residence before the onset of the disease, the scope of activities after the onset of the disease, or the care seeking medical institution is located, delegates the local CDC to carry out the epidemiological investigation on the pneumonia cases of 2019-nCoV. The investigation agency shall rapidly set up a field investigation team to clarify the purpose of the investigation and to determine the composition of the investigation team and team members’ responsibility and respective work according to the investigation plan. During the investigation, investigators should carefully wear recommended personal protective measures. In light of the on-site needs in dealing with the outbreak, the municipal, provincial, and national CDC will organize related healthcare professionals to participate in the fieldwork and form a joint investigation team with the previous one that arrived earlier to carry on field epidemiological investigation. Data report and analysis The CDC at the county/district level shall timely report their finished investigation forms or special investigation report via the network reporting system within 2 hours after completing the designated case investigation or clustered outbreak investigation. The specific reporting methods and web sites will be notified separately. The report on epidemiological investigation and analysis shall be submitted to the health administrative department at the same level and the CDC at the superior level simultaneously. Attachment: a case survey of pneumonia cases of a novel coronavirus infection annex Case survey of pneumonia cases with novel coronavirus infection (Third Edition) Questionnaire number: ________ ID number: ________ Basic information 1. Name: _____; if child, name of guardian _____ 2. Gender: □ Male □ Female 3. Date of birth: year, month, and age (if the date of birth is unknown, the actual age: ____ years or ____ months) 4. Current address: _____ Province _____ City ________ County (district) ______ Township (street) ________ Village (community) 5.Contact number: ___________________ 6. Date of Onset: Date __________ 7.Date of diagnosis: year, month, day __________ 8. Type of diagnosis: □ suspected case □ confirmed case □ test positive 9. Clinical severity: □ Asymptomatic infection □ Mild case □ General pneumonia □ Severe pneumonia □ Critical Pneumonia Onset and medical service-seeking 10. Symptoms and signs: □ fever: maximum temperature ______℃ □ chills □ dry cough □ sputum □ nasal congestion □ running □ sore throat □ headache □ fatigue □ muscle soreness □ joint soreness □ Shortness of breath □ Dyspnea □ Chest tightness □ Chest pain □ Conjunctival congestion □ nausea □ vomiting □ diarrhea □ abdominal pain □ other 11. Are there any complications: □ Yes □ No If yes, please choose (multiple choices): □ Meningitis □ Encephalitis □ Bacteremia / Sepsis □ Myocarditis □ Acute lung injury / ards □ Acute kidney injury □ Epilepsy □ Secondary bacterial pneumonia □ Other ______ 12. Is the blood routine test detected: □ No □ Yes If yes, test time: year, month and day______ (if multiple testers fill in the first test results) Test results: wbc (number of white blood cells)______ × 10 9 / l; l (number of lymphocytes) ______× 10 9 / l l (percent lymphocyte)______%; n (percent neutrophil)______%; Chest x-ray test whether there are imaging characteristics of pneumonia: □ not detected □ no □ yes If yes, test date______ 14. Is there a chest CT imaging feature of pneumonia: □ not detected □ no □ yes If yes, test date ______ 15. Whether to see a doctor after the onset: □ No (Yes If yes, date of first visit: year, month, day, ______name of the visiting hospital ______ 16.Is it quarantined: No, yes, if so, the quarantine start date: year, month, day______ 17. Whether hospitalization: □ No □ Yes, if yes, admission date: year, month, day ______ 18.Whether ICU treatment is accepted: □ No □ Yes, if so, date of ICU admission: year, month, day ______ Risk factors and exposure history 19. Whether the patient is the following specific occupational group: □ medical staff □ other staff in the hospital □ pathogenic microorganism detection staff □ wildlife contact personnel □ poultry and livestock breeding staff □ others ______ 20. Is the patient pregnant: □ Yes □ No 21. Previous medical history (multiple choices): □ no □ hypertension □ diabetes □ cardiovascular and cerebrovascular diseases □ Pulmonary diseases (such as asthma, pulmonary heart disease, pulmonary fibrosis, silicosis, etc.) □ Chronic kidney disease □ Chronic liver disease □ Immunodeficiency diseases □ Other _________ Have you had the following exposure history within 14 days before the onset or test was positive: 22.Is there a history of travel or residence in Wuhan or other areas with local cases of continuous transmission: □ History of Travel □ History of Residence □ No 23. Have you ever contacted a person who has fever or respiratory symptoms in areas where Wuhan or other local cases continue to spread: □ Yes □ No 24. Have you come in contact with people who have travel history or residence history in Wuhan or other areas where local cases have continued to spread: Yes □ No Is there a history of contact with confirmed cases, mild cases, or asymptomatic infections: Yes □ No 26. Does the patient have a cluster disease in the same family, work unit, child care institution or school? □ Yes □ No □ Unclear 27. Is there a history of medical institution visits: □ No □ Yes 28. Is there a farmer's market around the place of residence (village / residential building): □ Yes, about _____meters from your home □ No □ Unclear 29. Have you been to the farmer's market: □ Yes □ No □ Not sure If you have been there, the case is in the farmer's market: □ market practitioners □ supply / buyer □ consumers □ Others (including food delivery, finding someone, passing through, etc.) Laboratory testing 30. Specimen collection and detection of new coronavirus (multiple choices) Specimen type sampling time (year month day) Test results (Positive / negative / to be tested) Throat swab Nasal swab Sputum Tracheal secretions Tracheal aspirate Alveolar lavage fluid Blood specimen stool Other (fill in specimen name) Not collected (don't fill in sampling time and results) Survey unit: __________ Investigator's signature: __________ Survey time: year, month, day__________
Surveillance of P neumonitis C ases with N ovel C oronavirus I nfection (Third Edition , Jan 28, 2020) Since December 2019, a cluster of pneumonia cases infected with a n ovel f coronavirus (2029-nCoV) have been detected in Wuhan, Hubei Province. As the epidemic developed clustered cases and confirmed cases without a history of travel in Wuhan were reported in China, and c onfirmed cases with no clear history of exposure to market. In order to guide localities to detect and report the new coronavirus infection case s in a timely manner, better implement principles of early detection and early reporting strategy aiming to prevent the spread of the epidemic, this guidance plan is developed . Specific plans can be formulated separately by the local authorities . P urpose 1.1 To t imely detect and report the pneumonia cases and clustered cases with nCoV infection; 1.2 To understand the epidemic characteristics of novel coronavirus infections nationwide, and timely study and evaluate the development trend of the epidemic situation. 2. D efinition s 2.1 Suspected cases. 2.1.1 Epidemiological history: (1) Travel history or residence history in Wuhan or other areas with continuous local transmission case s within 14 days before the onset of illness; (2) Patients who have exposed to cases with fever or respiratory symptoms from Wuhan or other areas where local transmission cases continue to spread within 14 days prior to the illness onset; (3) Clustered onset of illness observed or epidemiological association existed with confirmed cases, mild cases, and asymptomatic infections. 2 .1 . 2 Clinical manifestations: (1) F ever; (2) W ith imaging characteristics of pneumonia; (3) T otal number of white blood cells is normal or decreased, or the lymphocyte count is reduced in the early stage of onset. Any one of the epidemiological history meets 1 and 2 or 2 and 3 of the clinical manifestations; if there is no clear epidemiological history, it meets all 3 of the clinical manifestations. 2.2 C onfirmed cases. Suspected cases have one of the following etiological evidence s : ( 1 ) Detection of 2019-nCoV by r eal-time fluorescence RT-PCR using r espiratory tract specimens or blood specimens shows positive; ( 2 ) Sequencing of viral genes, highly homologous to 2019-nCoV . 2.3 Mild cases. The clinical symptoms are mild, no obvious pneumonia manifestations, and 2019-nCoV test for respiratory specimens is positive. 2. 4 Asymptomatic infection. No clinical symptoms, respiratory specimens tested positive for 2019-nCoV . 2.5 Clustered outbreak . Clustered outbreak refers to the situation in which 2 or more confirmed cases, mild cases, or asymptomatic infections are found in a small area (such as a family, a construction site, a unit, etc.) within 14 days, and there exists possible human-to-human transmission caused by close contact , or likelihood of infection from co-exposure. 3.Case reporting 3.1 Case discovery. ( 1 ) All types of medical institutions at all levels should raise awareness of the diagnosis and reporting of pneumonia cases with 2019-nCoV infection. For cases with fever of unknown cause or cough, shortness of breath and other symptoms, attention should be paid to the travel and residence history to/in Wuhan City prior to the illness onset within the past 14 days where local virus transmission continue to spread ; whether they ha d exposure to patients with fever or respiratory symptoms in the above areas, and whether they have clustered onset or contact history with confirmed cases or 2019-nCoV infections. ( 2 ) Grassroots- level organizations should screen those with high risk who, over the past 14 days , ha d travel or residence history in Wuhan or other areas with local cases of continuous transmission, and have shown respiratory symptoms such as fever, chills, fatigue, diarrhea, conjunctival congestion, etc and arrange the sampling b y professional institutions. 3.2 Case report. When medical institutions at all levels and various levels find suspected cases, confirmed cases, mild cases, and asymptomatic infections, they should report directly to the network within 2 hours. The disease control institutions should immediately investigate and verify after receiving the report, and within 2 hours t he third-level confirmation and review of the report information should be completed through the online direct reporting system. Medical institutions that do not have the conditions for Internet-based online reporting system should immediately report to the local county (district) level disease control agency and complete filling in the infectious disease report card and send it out by mail within 2 hours. A fter receiving the report, the county (district) level disease control agency should immediately report directly to the web-based surveillance information system and follow up with possible corrections of subsequent information . For all cases diagnosed, select "new coronavirus-infected pneumonia" in list of the reported disease s , and select "suspected cases", "confirmed cases", and "tests positive" in the "case classification" . For those diagnosed with "mild cases" and "asymptomatic infections", the "test positive " is select ed. In the "clinical severity" classification, the "suspected cases" and "confirmed cases" are selected as "General pneumonia cases", "severe pneumonia cases" or "critical pneumonia cases" ; for " test positive" , select "asymptomatic infection" or "mild cases" . After the reported "suspected case" is confirmed, the case reporting unit should promptly correct it as the "confirmed case" in the "case classification". For "mild cases" and "asymptomatic infections", timely report and correct their status as clinical progress develops . For all cases, in the "Clinical Severity", timely corrections are made according to the disease progression, with the most severe state of the case as its final state. 3.3 Discovery and reporting of the incident. According to the requirements of “ National Emergency Plan for Public Health Emergencies ” and “ National Standards for the Management of Reports on Public Health Emergency - Related Information (Trial )”, the first confirmed cases of pneumonia and Clustered outbreak cases of 2019-nCoV infection in each county (district) disease control center in the ir jurisdiction should report directly to the surveillance system through the public health incident report management information system within 2 hours, and the event level can be selected as "unclassified" first. The health and health administration department shall, based on the incident investigation and subsequent progress, and the results of the risk assessment a fter grading an incident, the incident level can be adjusted accordingly, and the initial, progress and case report of the incident can be reported directly to the network in a timely manner. 3.4 Epidemiological investigation. At the county (district) level, the disease control agency should report cases of suspected pneumonia, confirmed cases, mild cases, and asymptomatic infections of 2019-nCoV infection, and complete the case investigation survey within 24 hours, and conduct close contact registration in a timely manner. For details, please refer to the Epidemiolog ical investigation of Pneumonia Cases Infected with 2019-nCoV (Third Edition) and Management of c lose contacts of p neumonia cases infected with 2019-nCoV (Third Edition) ''. After the county (district) level disease prevention and control institution completes the case investigation, the case investigation form should be reported in time through the web-based online reporting system. S pecific report instruction and website address will be provided by the Chinese Center for Disease Control and Prevention. The county (district) level disease control agency shall report the epidemiological investigation and analysis report to the health administrative department at the same level and the higher level disease control agency in a timely manner. 3.5 Specimen collection and laboratory testing. Medical institutions that treat suspected cases or Clustered outbreak cases should collect relevant clinical specimens of the cases and send the specimens to the local designated disease control institution, medical institution or third-party testing institution for relevant pathogenic testing as soon as possible. The collected clinical specimens include patients' upper respiratory tract specimens (such as throat swabs, nasal swabs, etc.), lower respiratory tract specimens (such as deep cough sputum, respiratory tract extracts, bronchial lavage fluid, alveolar lavage fluid, etc.), and eye conjunctiva Swabs, stool specimens, anticoagulant and serum specimens, etc. Sampler s should try to collect respiratory specimens (especially lower respiratory tract specimens) at the early stage of the onset of the case, serum in the acute phase within 7 days of onset, and in the recovery period of 3 to 4 weeks after the onset of disease. The specific requirements for clinical specimen collection and laboratory testing are described in the Guidelines for Laboratory Testing of Novel Coronavirus Infected Pneumonia (Third Edition) ''. Specimen collection, transportation, storage and testing are temporarily managed according to the class II of highly pathogenic pathogenic microorganisms, in accordance with the relevant Regulations on Biological Safety Management. 3.6 R equirements for c ase diagnos tic process . Aggregated cases of pneumonitis with 2019-nCoV infections in various regions shall be reviewed and confirmed by the local (municipal) level disease control agencies. For specimens of clustered cases, the original specimens shall be submitted to the provincial and national disease control agencies for further identification. If large-scale community transmission occurs, it shall be confirmed by the designated medical institution's laboratory after being evaluated and approved by the local (municipal) level disease control agency. The s pecimen testing at various levels of disease control institutions or medical institutions shall meet the requirements stipulated in Technical Guide for Laboratory Testing of Pneumonia Infected by Novel Coronavirus (Third Edition) ''.
General Office of National Health Commission Office of National Administration of Traditional Chinese Medicine The General Office of National Health Commission, Medical Letter (2020) No. 66 Notification on the Printing and Distribution of the Diagnosis and Treatment Plan for Pneumonia Patients Infected by the New-Type Coronavirus (Trial Version 3) The health commissions and TCM administration departments of all p rovinces, autonomous regions, municipalities directly under the Central Government and cities under separate state planning and Xinjiang Production and Construction Corps: In order to further guide the whole country to work scientifically and orderly on the diagnosis and medical treatment of pneumonia patients infected by the new-type coronavirus, we organized experts to revise the diagnosis and treatment plan and thus formulated the Diagnosis and Treatment Plan for Pneumonia Patients Infected by the New-Type Coronavirus (Trial Version 3) , which is hereby printed and distribut ed to you for your implementation. Contact person of the Medical Administration of National Health Commission: Du Qingyang Tel.: +86010-68792989 Fax: +86010-68791823 Contact person of Bureau of M edical Administration , National Administration of Traditional Chinese Medicine: Wang Jin Tel.: +86010-59957686 Fax: +86010-599576845 1574800 177165 4163695 311785 (Information disclosure form: voluntary disclosure) Diagnosis and Treatment Plan for Pneumonia Patients Infected by the New-Type Coronavirus (Trial Version 3) Since December 2019, some hospitals in Wuhan City, Hubei Province have successively discovered multiple cases of unexplained pneumonia with a history of exposure to Huanan Seafood Wholesale Market. The disease has now been confirmed as an acute respiratory infection caused by a new type of coronavirus. The cases collected so far show that the number of cases without a history of exposure to Huanan Seafood Wholesale Market is increasing, and there are confirmed clusters and confirmed cases without a history of travel to Wuhan. And there are confirmed cases in many countries and regions overseas from Wuhan and with no clear history of exposure to the wholesale market. Given that the source of the virus, the time of detoxification after infection and the pathog enesis are not clear, in order to better control the outbreak and reduce the probability of the disease’s domestic and international transmission, further strengthening the early detection, isolation and treatment of cases and reducing nosocomial infection s as much as possible are currently the key to control the source of infections and reducing morbidity. To improve the ability to treat the disease and reduce nosocomial infections as much as possible at the same time, we revised the Diagnosis and Treatmen t Plan for Pneumonia Patients Infected by the New-Type Coronavirus (Trial Version 2) . I Coronavirus Etiological Characteristics Coronavirus is a non-segmented, positive-sense, single-stranded RNA virus, belonging to the O rthocoronavirinae subfamily in the C oronaviridae family within the Nidovirales order. A ccording to serotype and genomic characteristics, the coronavirus subfamily is classified into four genera, α, β, γ and δ. There are currently six recognized types of co ronavirus that can infect humans, including 229E and NL63 (α coronavirus), OC43 and HKU1 (β coronavirus), MERS-related coronaviruses ( MERSr-CoV ) and SARS-related coronaviruses ( SARSr-CoV ). The coronavirus isolated from the lower respiratory tract of patien ts with unexplained pneumonia in Wuhan this time is a new type of coronavirus belonging to the genus β . Coronaviruses have an envelope, and the particles are round or oval, often polymorphic, with diameter being 50 to 200 nm. The S protein, located on the surface of the virus to form a rod-like structure, is one of the virus’ major antigen proteins and the main gene used for typing. The N protein encapsulates the viral genome and can be used as a diagnostic antigen. Most of the know-how about the physical and chemical properties of coronavirus comes from the research on SARS- CoV and MERS- CoV . The virus is sensitive to heat. Exposure to 56 °C for 30 minutes and l ipid solvents such as ethyl acetate, 75% ethanol, chlorine-containing disinfectant, peracetic aci d, and chloroform can effectively inactivate the virus. Chlorhexidine has not been effective in inactivating the virus. II Clinical Characteristics of the Outbreak 1. Clinical manifestations Main manifestations are fever, fatigue, and dry cough. Nasal congestion, runny nose and other upper respiratory symptoms are rare. About half of the patients develop dyspnea after one week. In severe cases, patients progress rapidly to acute respiratory distress syndrome, septic shock, metabolic acidosis diffi cult to correct, and coagulopathy. It is worth noting that for severe and critically ill patients, their fever can be moderate to low, or even barely noticeable. Some patients have mild onset symptoms and maybe no fever, and they usually recover after one week. Most patients have good prognosis; and a small number of patients are critically ill and even die. 2. Laboratory tests In the early stages of the disease , the total number of peripheral white blood cells is normal or decreases, the lymphocyte count decreases, and some patients see an increase in liver enzymes, muscle enzymes, and myoglobin. Most patients have elevated C-reactive protein and erythrocyte sed imentation rate and normal procalcitonin. In severe cases, D-dimer increases and peripheral blood lymphocytes progressively decrease. 3. Chest imaging In the early stage, imaging shows multiple small patchy shadows and interstitial changes, apparent in th e outer lateral zone of lungs. As the disease progresses, imaging then shows multiple ground glass opacities and infiltration in both lungs. In severe cases, pulmonary consolidation may occur, and pleural effusion is rare. III. Case Definition 1 Suspected cases (cases originally placed under observation) Cases meeting both of the following two criteria : (1) Epidemiological history History of travel to or residence in Wuhan within two weeks before the onset of the disease; or in contact with pati ents with fever and concomitant respiratory symptoms from Wuhan within 14 days before the onset of the disease; or a cluster. (2) Clinical manifestations (2.1) Fever; (2.2) The aforementioned imaging characteristics of pneumonia; (2.3) Normal or decreased total number of white blood cells or decreased lymphocyte count in the early stage of onset. 2. Confirmed cases On the basis of meeting the criteria for suspected cases, sputum, throat swabs, lower respiratory tract secretions and other specimens are shown by real-time fluorescent RT-PCR tests to be nuclei acid positive for the new-type coronavirus; or viral gene sequencing is highly homologous to the already known new coronavirus. 3. Severe cases Cases m eeting any of the following criteria: (1) Increased respiratory rate ( ≧ 30 breaths/ min), difficulty in breathing, and cyanosis of lips; (2) When inhaling air, oxygen saturation is ≦ 93% (3) A rterial partial pressure of oxygen (PaO 2 )/ fraction of inspired oxygen (FiO 2 ) ≦ 300mmHg (l mmHg=O. 133kPa); (4) Pulmonary imaging shows multilobular lesions or lesion progression exceeding 50% within 48 hours; (5) With other concomitant clinical conditions that require hospitalization. 4. Critical cases Cases meeting any of the following criteria: (1) Respiratory failure and requiring mechanical ventilation; (2) Shock; (3) With other concomitant organ failure that requires ICU monitoring and treatment. IV. Differential Diagnosis Main candidate diseases to be distinguished from include known viral pneumonia, for example, pneumonia caused by influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human metapneumovirus, SARS coronavirus; and mycoplasma pneumoniae and chlamydia p neumonia, and bacterial pneumonia. In addition, non-infectious diseases such as vasculitis, dermatomyositis and organizing pneumonia are also candidate diseases to be distinguished from. V Case Discovery and Reporting Health professionals in medical insti tutions of all types and at all levels, upon discovering suspected cases that meet the definition, should immediately isolate and treat them and report to the competent departments of the medical institution and the disease control center in the locality. The medical institution involved should organize its own experts or those in the district (county) for consultation; if the suspected case is not diagnosed as viral pneumonia caused by common respiratory pathogens, specimens should be collected in time for pathogen detection. Suspected cases can be released only after they test nuclei acid negative for respiratory pathogen twice consecutively (sampling interval being at least one day). VI Treatment T reatment venue determined according to the severity of the disease Suspected and confirmed cases should be isolated and treated at designated hospitals with effective isolation, protection and prevention conditions in place. A suspected case should be treated in isolation in a single room. Confirm ed cases can be treated in the same room. Critical cases should be admitted to ICU as soon as possible. General treatment (1) Letting patients rest in bed and strengthening support therapy; ensuring sufficient caloric intake for patients; heeding to thei r water and electrolyte balance to maintain internal environment stability; closely monitoring vital signs and oxygen saturation. (2) Monitoring blood routine result, urine routine result, c-reactive protein (CRP), biochemical indicators (liver enzyme, my ocardial enzyme, renal function etc.), coagulation function according to patients ’ conditions, and performing arterial blood gas analysis if necessary, and re-examining chest imaging. (3) Timely providing effective oxygen therapy, including nasal catheter and mask oxygenation, and if necessary, nasal high-flow oxygen therapy, non-invasive or invasive mechanical ventilation etc., according to changes in oxygen saturation. (4) Antiviral therapy: There are currently no effective antiviral drugs. Hospitals can try aerosols of interferon alpha (5 million U each time for an adult, add 2 ml of sterilized water for injection twice daily); giving patients lopinavir/ ritonavir, 2 capsules a time and 2 times a day. (5) Antibiotic drug treatment: Blind or inappropriate use of antibiotic drugs should be avoided, especially in combination with broad-spectrum antibiotics. Bacteriological monitoring should be strengthened, and antibiotic drugs should be applied timely when there is evidence of secondary bacter ial infection. (6) Others: G lucocorticoids should be used for a short period (3 to 5 days) as appropriate , depending on the patient ’ s severity of dyspnea and chest imaging progress. The recommended dose is not to exceed the equivalent to 1- 2 mg/ kg / d of methylprednisolone. 3. Treatment of severe and critical cases (1) Treatment principle: On the basis of symptomatic treatment, hospitals should proactively prevent complications, treat underlying medical conditions, prevent secondary infections, and time ly provide organ function support. (2) Respiratory support: non-invasive mechanical ventilation for 2 hours. If that brings no improvement in condition, or the patient cannot tolerate non-invasive ventilation, or airway secretions increase, or if there i s severe cough or hemodynamic instability, then non-invasive mechanical ventilation should timely transition to invasive mechanical ventilation. Invasive mechanical ventilation adopts the low tidal volume “ pulmonary protective ventilation strategy ” to red uce ventilator-related lung injury. When necessary, prone position ventilation, lung recruitment or extracorporeal membrane oxygenation (ECMO), among others, can be used. (3) Circulatory support: On the basis of adequate fluid resuscitation, hospitals sh ould improve microcirculation, use vasoactive drugs, and perform hemodynamic monitoring when necessary. VII Criteria for Removal of Isolation and Discharge Patients meeting the following criteria can be removed from medical isolation and discharged or be transferred to other departments to treat other medical conditions, if any: body temperature is back to normal for more than 3 days; respiratory symptoms improve obviously; pulmonary imaging shows obvious absorption of inflammation, and nuclei acid tests negative for respiratory tract pathogen twice consecutively (sampling interval being at least one day). VIII Transportation Principles Patients should be transported in special vehicles, transportation personnel should have proper perso nal protection and vehicles should be disinfected. IX Nosocomial Infection Control Nosocomial infection control should be executed in accordance with the requirements of Guidelines for the Prevention and Control of Infection by the New-Type Coronavirus in Medical Institutions (First Edition) formulated by the National Health Commission. The General Office of National Health Commission Printed and distributed on January 22, 2020 Proofreading by Du Qingyang
Saatja: 林 昀 <
[email protected]>
Saadetud: 08.02.2020 07:55
Adressaat: <
[email protected]>; <
[email protected]>;
<
[email protected]>; <
[email protected]>; <
[email protected]>; SM Info
<
[email protected]>; <
[email protected]>; <
[email protected]>; <
[email protected]>;
<
[email protected]>; <
[email protected]>; <
[email protected]>;
<
[email protected]>; <
[email protected]>; <
[email protected]>;
<
[email protected]>; <
[email protected]>
Teema: Relevant technical guidelines for 2019-nCoV
Manused: 第五版诊疗方案.pdf; 1 Epidemiological Investigation - 2019 Novel Coronavirus
V3 -final 20200128.docx; 2 Surveillance of 2019-nCoV Pneumonia V3-final-20200128.docx;
3 Management of close contacts - 2019 Novel Coronavirus V3_-final-20200128.docx; eng 6
Diagnosis and treatment protocol for 2019 nCOV Version 3.docx; Epidemic update &
risk_assessment of 2019-nCoV 28Jan2020-China CDC.pdf; Labtest procedure 2019-nCoV-
V1.0-EN.doc
Dear colleagues from Central and Eastern European Countries,
Please find attached the relevant technical guidelines adopted in China for the current nCoV
outbreak, as attached.
Thank you for your kindness.
Best wishes,
LIN Yun (Ms.)
European and American Affairs
Department of International Cooperation
National Health Commission, China
Tel: +86 10 6879 2502
Fax: +86 10 6879 2285
Management of C lose Contacts of P neumonia Cases infected with 2019-nCoV (Third Edition , Jan 28, 2020 ) In order to determine and manage close contacts of pneumonia cases infected with the n ovel coronavirus, and effectively control the spread of the disease, based on the current knowledge about the n ovel coronavirus infection and the estimated incubation period of up to 14 days , this protocol for close contacts management is developed . 1. Identification criteria Close contact refers to those who have been exposed to suspected cases, confirmed cases, and mild cases who already present the symptoms , and those with asymptomatic infection but being tested as positive with coronavirus , and find themselves in one of the following contact situations, but have not taken effective pr ecautions : 1.Live together, study, work, or have close contacts, such as working close to or sharing the same classroom or living in the same house; 2.Medical staff, family members, or other people who have similar close contact for diagnosis, treatment, visiting cases, such as visiting or staying in a closed environment, other patients in the same ward and their accompanying persons ; 3.Take the same transportation tool and have close contact with the case , including care-providers and nursing staff, accompanying persons (family, colleagues, friends, etc.) on the transportation, or after investigating and assess ment, other passengers and attendants who have possibility of close contact with the cases (suspected cases, confirmed diagnosis) and infected people (mild cases, cases with asymptomatic infections). The method to determin e the close contact s on different vehicles is shown in Annex 1. 4. Other close contacts after investigation and evaluation by the on-site investigators. The identified close contacts are required to fill in the “ Registration Form for Close Contacts of Cases with 2019-nCov Pneumonia (Appendix 1) ” . 2. Management requirements Contact management. Health administrative departments in various places will organize and implement medical observations of close contacts with relevant departments. Those who refuse to do so may be assisted by local public security agencies to take compulsory isolation measures. When implementing medical observations, the reasons, isolation period , legal basis, precautions, and disease-related knowledge of medical observations should be informed to the close contacts in writing or orally, as well as the medical and health institutions responsible for medical observations, and their contacts and contact information. Close contacts usually receive medical observation at home , and those who cannot isolate the mselves for medical observ ation at home can be arrange d in centralized isolation place for observation. The medical observation period is 14 days after the last unprotected exposure with the case and the infected person. If the close contact of the confirmed case and infected person is tested 2019-nCoV negative during the medical observation period, he/she must continue until the observation period expires. After the suspected case is ruled out, close contac ts with him/her can be release d from the medical observation. Close contacted isolated at home or centralized medical observation place should live relatively independently, minimize the contact with co-residents . Strict c leaning and disinfect ion should be made at medical observation place, and avoid cross-infection. Close contact should not go out during the observation period. If you must go out, you should gain the approval from the responsible medical observation management staff, wear disposable surgical masks , and avoid going to crowded places . Health risks shall be notified to general contacts other than those who are in close contact with the cases in the same transportation such as airplanes, trains, and ships, or in the same living, studying, and working environment, and urge them to report symptoms of respiratory infections such as fever, cough, and other symptoms as diarrhea, conjunctival congestion to a doctor and s eek medical attention in a timely manner, and actively inform the recent history of activities. Measures during medical observation. During medical observation, the following measures should be taken: The staff of the designated medical and health institution will take a temperature measurement every morning and evening for close contacts and ask about their health status, fill in close-contact medical observation record form, “ Medical Observation Registration Form for Close Contacts of Cases with 2019-nCoV Pneumonia ” (Appendix 2), and provide necessary assistance and guidance. “ Daily Report of Medical Observation Statistics of Close Contacts of Cases with 2019-nCoV Pneumonia ” (Appendix 3) and “ Daily Statistical Summary Table of Medical Observations for Close Contacts of Cases with 2019-nCoV Pneumonia ” (Appendix 4) are provided as a reference to summarize the medical observations of close contacts. The personnel who implement medical observation should take strict personal protection.For the protective measures, please refer to the `` Personal Protection Program for Specific Personnel (First Edition) ''. During medical observation, once the close contact has any symptoms (including fever, chills, dry cough, sputum, nasal congestion, runny nose, sore throat, headache, fatigue, muscle soreness, joint pain, shortness of breath, dyspnea, chest tightness, Conjunctival congestion, nausea, vomiting, diarrhea, abdominal pain, etc. ), it is compulsory to immediately report to the local health and health department, and send it to a designated medical institution for diagnosis and treatment, collect specimens for laboratory testing and investigation. If the results of the investigation are suspected cases, confirmed diagnosis Cases or mild cases, medical observations should be made to those who are in close contact with them. When the medical observation period expires, if there is no abnormality in close contacts, the medical observation can be terminated in time. (3) Centralized medical observation sites. The selection of the central ized medical observation site and the requirements for internal facilities are as follows: 1) Centralized medical observation sites should be selected in the direction of downwind, relatively remote areas with convenient transportation; relatively far away from the densely populated area (at least greater than 500 meters), and relatively independent places. No centralized isolation places should be set up in medical institutions. 2) The interior of the centralized medical observation site is divided into zone s based on their functions , and can be divided into living zone , material supply zone , and wards, etc., and the zone s must be clearly marked. Infrastructure that guarantees the normal life of isola ted individuals should be provided with appropriate ventilation and capable of supporting the implementation of daily disinfection measures. 3) It should have an independent septic tank. Before entering the municipal drainage pipe network, the sewage should be disinfected, and the chlorine-containing disinfectant should be put in regularly. After 1.5 hours of disinfection, the total residual chlorine is 10 mg / L. Treated waste water shall meet the drainage requirements by Water Pollutant Discharge Standards for Institutions (GB18466-2005) . If there is no independent septic tank, use special containers to collect excreta, sterilize and discharge, and refer to the General Rules for Disinfection of Epidemic Sources (GB19193-2015) for detailed instruction . S ingle room s shall be provided at the centralized medical observation site . Once symptoms such as fever, cough and other respiratory infections, as well as diarrhea, conjunctival congestion and other symptoms occur, promptly conduct specimen collection and testing. Appendix : 1. Guidelines for identifying close contact s with cases on vehicles 2. Registration Form for Close Contacts of 2019-nCoV Pneumonia Cases 3. Medical Observation Registration Form for Close Contacts of 2019-nCov Pneumonia Cases 4. Daily Report of Medical Observation for Close Contacts of 2019-nCoV Pneumonia Cases 5. Daily Summary Table on Medical Observations for Close Contacts of 2019-nCoV Pneumonia Cases Appendix 1 Guidelines for Identifying C lose C ontact s of Cases on V ehicles A ircraft 1.In general, all passengers in the same row and three rows in front and back of case ’ s seat in civil aircraft cabins, as well as flight attendants who provide cabin services in the above areas, are considered as close contacts. Other passengers on the same flight are consider ed as general contacts. 2. A ll people who t ake the same civil aircraft as the case, which is not equipped with a high-efficiency particulate filter device , are close contacts . 3.Other persons who are known to have close contact with the case. Railway passenger trains In a fully enclosed air-conditioned train, all passengers and attendants in the same carriage where the case is located in either hard seat, hard sleeper or soft sleeper car . 2.Take non-fully enclosed ordinary trains, passengers in the same compartment with soft sleepers, or passengers in the same and adjacent compartments in the carriage with the hard seat (hard sleeper), and all attendants serving the se area s. 3.Other persons who are known to have close contact with the case. Cars 1.When travelling in a fully air-conditioned bus, all p assenger s traveling in the same car as the case. 2.When traveling in a ventilated ordinary passenger car, passengers in the same and 3 rows in front of and behind the row where the case sat . 3.Other persons who are known to have close contact with the case. Ships All personnel in the same cabin as the case and flight attendants serving the cabin. If anyone who has contact with a patient who ha d severe symptoms such as high fever, sneezing, coughing, vomiting, regardless of the length of time, he/she should be evaluat ed as close contact. Appendix 2 Registration Form for Close Contacts of 2019-nCoV Pneumonia Cases Name contact details gender age Relationship to case Earliest contact time Last contact time Contact frequency Place of contact Way of contact Remarks (specify single exposure time) Contact frequency: ① often ② average ③ occasionally Contact location: ① At home ② Medical institution ③ Work place ④ Entertainment place ⑤ Other (please specify in the form) Contact method: ①Same meal ②Live together ③Same room ④Same bed ④Same room work and study ⑥Diagnosis, Nursing service ⑦ Same ward ⑧ Entertainment activities ⑨ Other (please specify in the form) Appendix 3 Medical Observation Registration Form for Close Contacts of 2019-nCov Pneumonia Cases □ Suspect ed □ Confirmed □ Case Name of Infected Person: Contact Phone: : Date of Onset: : Number Name gender age current address of residence Start ing date of o b serv ation Clinical manifestation Body temperature (℃) Dry cough other 1 2 3 4 5 6 7 1 2 3 4 5 6 7 1 2 3 4 5 6 7 Note: 1.This table is suitable for use by health personnel who have medical observation of cases of pneumonia infected with 2019-nCoV and those who are in close contact with the infected person. 2. In "Do you have the following clinical manifestations?", Fill in the measured temperature with "Body temperature", and "cough" appear "√", otherwise "×"; fill in the corresponding code for other symptoms ① chill ② expectoration ③ nasal congestion ④ runny nose ⑤ pharynx Pain ⑥ headache ⑦ fatigue ⑦ muscle soreness = 9 \* GB3 ⑨ Joint soreness = 10 \* GB3 ⑩ Shortness of breath, chest tightness, conjunctival congestion, nausea, vomiting, diarrhea, abdominal pain Filling unit: Filler: Filling date: Y ear, M onth, D ay Appendix 4 Daily Report of Medical Observation for Close Contacts of 2019-nCoV Pneumonia Cases Street / Community or Home Date of first medical observation Cumulative number Medical observer Number s with abnormal clinical manifestations Date to terminate the medical observation of the l ast close contact Numbers under the o bservations Number of Dismissal s Today New for today Today Cumulative number New for today Cumulative number total - Note: 1. This form is applicable to the medical staff who report the situation of medical observation to the upper-level coordinators . 2. Abnormal clinical manifestations: fever, cough, shortness of breath and other symptoms. 3.The cumulative numbers in the table refer to the aggregated data about medical observations made for close contacts. Filling unit: (medical health institution) Filling person: Filling date: year, month, day Appendix 5 Daily Summary Table of Medical Observations for Close Contacts of 2019-nCoV Pneumonia Cases Prefecture Date of first observation Cumulative number of observers Medical observer Number s with abnormal clinical manifestations Date to terminate the medical observation of the l ast close contact Numbers under the o bservations Number of Dismissal s Today New for today Today Cumulative number New for today Cumulative number total Note: 1.This table can be used for statistical summary of city and district CDCs. 2. Abnormal clinical manifestations: fever, cough, shortness of breath and other symptoms. 3.The cumulative numbers in the table refer to the aggregated data since the close observation of medical observations of close contacts. Form filling unit: ( CDC ) Form F illing person: Form filling date: year, month and day